The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Approval of abatacept for prophylactic treatment of aGvHD
The U.S Food and Drug Administration (FDA) announced on December 15, 2021, that abatacept has been approved for prophylactic treatment of acute graft-versus-host disease (aGvHD) in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX). This approval is for use in patients from 2 years of age who received a hematopoietic stem cell transplant (HSCT) from a matched or 7/8 human leukocyte antigen (HLA)-mismatched unrelated donor. This is the first agent to be approved for the prevention of aGvHD.1 Abatacept was previously granted a breakthrough designation for the prevention of aGvHD.
This decision has been made based on data from two studies. The first is GvHD-1 (NCT01743131), a phase II, multicenter, randomized, placebo-controlled trial of patients (N = 186) who were given an 8/8 HLA-matched HSCT and were treated with abatacept or a placebo along with CNI + MTX.
Results from this trial did not show a significant improvement in Grade III–IV aGvHD-free survival at Day 180 in patients receiving abatacept during the trial. However, at Day 180 the overall survival rate was 97% (95% confidence interval [CI], 89–99%) compared with 84% (95% CI, 73–91%) for the patients receiving abatacept compared with the placebo, respectively (hazard ratio, 0.33; 95% CI, 0.12–0.93%). In addition, the Grade II-IV aGvHD-free survival for patients receiving the placebo was 32% (95% CI, 21–43%) compared with 50% (95% CI, 38–61%) for patients treated with abatacept at Day 180 post HSCT (hazard ratio, 0.54; 95% CI, 0.35–0.83%).
The second trial is the GvHD-2 clinical study of 54 patients who received a 7/8 HLA-matched HSCT and were treated with abatacept for aGvHD prophylaxis + CNI + MTX. This group was compared with 162 patients who received only CNI + MTX. The data were provided by the Center for International Blood and Marrow Transplant Research (CIBMTR).
The results of this study showed that at 180 days post HSCT the overall survival rate was 98% (95% CI, 78–100%) for patients treated with abatacept + CNI + MTX compared with 75% (95% CI, 67–82%) for patients who were given CNI + MTX only.
Abatacept acts as a T-cell costimulation blocker and has also been approved for the treatment of rheumatoid arthritis.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content